Terri Goldberg

460 total citations
11 papers, 98 citations indexed

About

Terri Goldberg is a scholar working on Oncology, Hepatology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Terri Goldberg has authored 11 papers receiving a total of 98 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Oncology, 5 papers in Hepatology and 3 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Terri Goldberg's work include Hepatocellular Carcinoma Treatment and Prognosis (5 papers), Liver physiology and pathology (4 papers) and Lung Cancer Treatments and Mutations (3 papers). Terri Goldberg is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (5 papers), Liver physiology and pathology (4 papers) and Lung Cancer Treatments and Mutations (3 papers). Terri Goldberg collaborates with scholars based in United States, Italy and France. Terri Goldberg's co-authors include Giovanni Abbadessa, Bruno Daniele, Markus Peck‐Radosavljevic, Lorenza Rimassa, Jordi Bruix, Armando Santoro, Camillo Porta, Maria Lamar, Richard S. Finn and Nevena Damjanov and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.

In The Last Decade

Terri Goldberg

11 papers receiving 98 citations

Peers

Countries citing papers authored by Terri Goldberg

Since Specialization

Citations

This map shows the geographic impact of Terri Goldberg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Terri Goldberg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Terri Goldberg more than expected).

Fields of papers citing papers by Terri Goldberg

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Terri Goldberg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Terri Goldberg. The network helps show where Terri Goldberg may publish in the future.

Co-authorship network of co-authors of Terri Goldberg

This figure shows the co-authorship network connecting the top 25 collaborators of Terri Goldberg. A scholar is included among the top collaborators of Terri Goldberg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Terri Goldberg. Terri Goldberg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

#	Work	Indexed citations
1	Phase I study of the AXL inhibitor DS-1205c in combination with osimertinib in subjects with metastatic or unresectable EGFR-mutant NSCLC 2018 ·Annals of Oncology ·David Planchard, Pasi A. Jänne, Helena A. Yu, Denis Moro‐Sibilot, Terri Goldberg, Xuemin Gu, (unknown), Jodi L. McGill, Channing Yu, Eric D. Slosberg	1
2	First-in-human study of DS-6051b in patients (pts) with advanced solid tumors (AST) conducted in the US. 2018 ·Journal of Clinical Oncology ·Kyriakos P. Papadopoulos, Leena Gandhi, Pasi A. Jänne, Sai‐Hong Ignatius Ou, Alice T. Shaw, Terri Goldberg, Jonathan Greenberg, Xuemin Gu, Masaya Tachibana, Giorgio Senaldi, Ryota Shiga, Hamim Zahir, Kenji Nakamaru, Erkut Borazanci	15
3	Tumor biopsy and patient enrollment in clinical trials for advanced hepatocellular carcinoma 2017 ·World Journal of Gastroenterology ·Lorenza Rimassa, María Reig, Giovanni Abbadessa, Markus Peck‐Radosavljevic, William Proctor Harris, Vittorina Zagonel, Davide Pastorelli, Elena Rota Caremoli, Camillo Porta, Nevena Damjanov, Hitendra Patel, Bruno Daniele, Maria Lamar, Brian Schwartz, Terri Goldberg, Armando Santoro, Jordi Bruix	10
4	Second-line tivantinib (ARQ 197) vs placebo in patients (Pts) with MET-high hepatocellular carcinoma (HCC): Results of the METIV-HCC phase III trial. 2017 ·Journal of Clinical Oncology ·Lorenza Rimassa, Eric Assénat, Markus Peck‐Radosavljevic, Vittorina Zagonel, Marc Pracht, Elena Rota Caremoli, Philippe Mathurin, William Proctor Harris, Luigi Bolondi, María Reig, Nevena Damjanov, Bruno Daniele, Camillo Porta, Vincenzo Mazzaferro, Giovanni Abbadessa, Brian Schwartz, Maria Lamar, Terri Goldberg, Armando Santoro, Jordi Bruix	33
5	Abstract CT024: First-in-human phase 1 dose-escalation study of DS-6051b, an oral ROS1 and NTRK inhibitor, in subjects with advanced solid tumors 2016 ·Cancer Research ·Kyriakos P. Papadopoulos, Erkut Borazanci, Daniel D. Von Hoff, Leena Gandhi, Amita Patnaik, Masaya Tachibana, Hamim Zahir, (unknown), Terri Goldberg, Giorgio Senaldi, (unknown)	2
6	Tivantinib, a New Option for Second-line Treatment of Advanced Hepatocellular Carcinoma? The Experience of Italian Centers 2015 ·Tumori Journal ·Lorenza Rimassa, Armando Santoro, Bruno Daniele, Domenico Germano, Antonio Gasbarrini, Stefania Salvagni, Gianluca Masi, Giovanni Abbadessa, Maria Lamar, Terri Goldberg, Camillo Porta	6
7	A randomized, open-label phase II study of efatutazone in combination with FOLFIRI as second-line therapy for metastatic colorectal cancer (mCRC). 2014 ·Journal of Clinical Oncology ·John L. Marshall, Dale E. Shuster, Terri Goldberg, Catherine Copigneaux, Shuquan Chen, Hamim Zahir, (unknown), Mansoor N. Saleh, Michael J. Pishvaian, Mirta Varela, (unknown), Nicolas Lazaretti, (unknown), (unknown), (unknown), (unknown)	4
8	Tivantinib in MET-high hepatocellular carcinoma patients and the ongoing Phase III clinical trial 2014 ·PubMed ·Lorenza Rimassa, Camillo Porta, Ivan Borbath, Bruno Daniele, Richard S. Finn, Jean‐Luc Raoul, Lawrence H. Schwartz, Aiwu Ruth He, Joerg Trojan, Markus Peck‐Radosavljevic, Giovanni Abbadessa, Terri Goldberg, Armando Santoro, Jordi Bruix	14
9	Abstract CT311: A randomized, open-label phase 2 study of efatutazone and erlotinib as second- or third-line therapy for non-small cell lung cancer (NSCLC) 2014 ·Cancer Research ·Ana B. Oton, Byoung Chul Cho, Myung‐Ju Ahn, Sang‐We Kim, (unknown), Chirag Desai, Dale E. Shuster, Terri Goldberg, Hamim Zahir, (unknown), Shuquan Chen, (unknown), Joachim von Pawel	2
10	Metiv-HCC: A phase III clinical trial evaluating tivantinib (ARQ 197), a MET inhibitor, versus placebo as second-line in patients (pts) with MET-high inoperable hepatocellular carcinoma (HCC). 2013 ·Journal of Clinical Oncology ·Armando Santoro, Camillo Porta, Lorenza Rimassa, Ivan Borbath, Bruno Daniele, Richard S. Finn, Jean‐Luc Raoul, Lawrence H. Schwartz, Aiwu Ruth He, Jörg Trojan, Markus Peck‐Radosavljevic, Giovanni Abbadessa, Terri Goldberg, Jordi Bruix	9
11	A phase I study of E7820 in combination with Cetuximab in patients (pts) with advanced solid tumors 2008 ·Journal of Clinical Oncology ·Anthony B. El-Khoueiry, (unknown), Kevie Feit, H.J. Lenz, (unknown), (unknown), Terri Goldberg, Peter Conti, Daniel P. Rossignol	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact